

A FORENSIC INVESTIGATION INTO THE PRESENCE OF PHOSPHODIESTERASE 5 INHIBITORS AS ADULTERANTS IN HERBAL REMEDIES

by Ahmad Yusri Mohd Yusop

Thesis submitted in fulfilment of the requirements for
the degree of

Doctor of Philosophy (Science)

under the supervision of

Professor Shanlin Fu and Doctor Linda Xiao

University of Technology Sydney
Faculty of Science

September 2020

CERTIFICATE OF ORIGINAL AUTHORSHIP

I, Ahmad Yusri Mohd Yusop declare that this thesis, is submitted in fulfilment of the requirements for the award of Doctor of Philosophy (Science), in the Faculty of Science at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research is supported by the Australian Government Research Training Program.

Production Note:

Signature: Signature removed prior to publication.

Date: 17/09/2020

ABSTRACT

The proliferation of herbal-based male sexual performance products, particularly those adulterated with phosphodiesterase 5 (PDE5) inhibitors, has sparked grave public health and food safety concerns. The advent of their unapproved analogues presents an additional challenge to forensic drug testing laboratories, as these adulterants may evade detection during routine screening. A comprehensive strategy is warranted to address these problems and protect consumers' health and well-being. This study investigated the presence of PDE5 inhibitors as adulterants in herbal remedies, using a two-tier screening strategy of rapid qualitative assay and confirmatory analytical analysis.

A bioactivity-based PDE5 inhibition assay was established using fluorescein-labelled cyclic-3',5'-guanosine monophosphate as substrates to PDE5 enzyme. The PDE5 inhibitions, measured using a fluorescence polarisation technique, was applied to 50 herbal-based food samples. The results were in agreement with the confirmatory analytical analysis for all food products, except for the instant coffee premix samples, postulated due to the presence of caffeine. The assay, nevertheless, exhibited a promising potential to rapidly screen PDE5 inhibitors in various types of food products, except those containing naturally-occurring phosphodiesterase inhibitors.

A confirmatory liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analysis was developed using 23 target analytes; selected to represent different groups of PDE5 inhibitors, based on their structural similarities. The targeted analysis was primarily optimised to mitigate the matrix effect (ME), via chromatographic separation, sample extraction, and sample dilution. The insignificant ME percentages, within -9.2%–8.8% for all target analytes in food and pharmaceutical matrices, were evidenced with satisfactory validation results; notably, the accuracy was within 77.4%–124.7%. The development, optimisation, and validation of the targeted analysis provided a solid foundation for suspected-target and non-targeted screenings. The suspected-target screening employed a library comprising 95 PDE5 inhibitors, providing extended coverage of known analytes. Contrarily, the non-targeted screening adopted top-down and bottom-up approaches to flag novel PDE5 inhibitors analogues based on common fragmentation patterns of target analytes.

The confirmatory LC-HRMS analysis was applied to 50 herbal-based food samples and 52 herbal-based pharmaceutical samples. The targeted analysis and the suspected-target screening identified 11 target analytes and detected five suspected analytes, respectively, from 74 adulterated samples. The non-targeted screening returned insignificant signals, indicating the absence of potentially novel analogues. Some of these samples contained up to five different PDE5 inhibitors and quantified at supratherapeutic level, making them unsafe for consumption. The comprehensive strategies provide a superior approach to curb the widespread adulteration of herbal remedies, thus, safeguarding the public's health.

ACKNOWLEDGEMENTS

First and foremost, I would like to thank my principal supervisor, Professor Shanlin Fu. He has patiently guided me throughout my PhD journey and shared his knowledge while entrusting me to take charge of my research. I attribute the completion of this research to his guidance, support, and encouragement. He is my mentor, and I am forever in debt to him.

I also wish to express my sincere gratitude to my co-supervisor, Dr Linda Xiao, for her consistent support and guidance during the running of this research. She continuously encouraged me and was always willing and keen to assist in any way she could throughout the research project.

My sincere appreciation goes to all the academic and professional staff who have supported me throughout my time at UTS. Thanks to Dr Ronald Shimmon for helping me in the laboratories as well as the training on NMR spectroscopy, and to Dr Verena Taudte and Dr Dayanne Bordin for the technical support with LC-MS/MS instruments. I also very much valued the feedback I have received from the forensic science and toxicology research group to improve my research. To Professor Claude Roux and the Centre for Forensic Science, thank you for providing financial support, particularly with the attendance of conferences.

I extend my warmest thanks to my family and friends for their moral support, which made my journey endurable. Finally, I am grateful to the Ministry of Health Malaysia for the Study Leave with Full Pay and Federal Training Reward that helped me to achieve my dream.

Table of contents

	Page
Certificate of original authorship	i
Abstract	ii
Acknowledgements	iv
List of tables	xii
List of figures	xviii
List of equations	xxiv
List of abbreviations and symbols	xxvi
List of peer-reviewed journal publications	xxxiii
List of manuscripts submitted to peer-reviewed journal publications	xxxiv
List of peer-reviewed conference proceedings	xxxv
CHAPTER 1 Introduction	1
1.1 Background	1
1.2 Aim and research objectives	4
1.3 References	5
CHAPTER 2 Literature review	8
2.1 Phosphodiesterase enzyme	8
2.2 Phosphodiesterase 5 enzyme	11
2.3 Phosphodiesterase inhibitors	13
2.4 Phosphodiesterase 5 Inhibitors	15
2.4.1 Background	15
2.4.2 Approved PDE5 inhibitors	16

2.4.3	Mechanism of action	20
2.4.4	Chemical structure	21
2.4.5	Safety profiles	24
2.5	Adulteration of herbal remedies	27
2.5.1	Background	27
2.5.2	Male sexual performance products	28
2.5.3	PDE5 inhibitors and their analogues	29
2.6	Analysis of PDE5 inhibitors	36
2.6.1	Background and challenges	36
2.6.2	Sample extraction	39
2.6.3	Techniques used for the detection and identification of PDE5 inhibitors	39
2.7	References	46
CHAPTER 3	Comparison of sample extraction techniques for the determination of erectile dysfunction drugs as adulterants in selected food products	76
3.1	Foreword	76
3.2	Abstract	78
3.3	Introduction	80
3.4	Materials and methods	83
3.4.1	Chemicals and reagents	83
3.4.2	Standard solution preparation	84
3.4.3	Sample collection and storage	84
3.4.4	Sample extraction procedures	85

3.4.5	LC-QTOF-MS conditions and data analysis	88
3.4.6	Comparison of sample extraction techniques	89
3.4.7	Analytical method validation	91
3.5	Results and discussion	93
3.5.1	Method development and optimisation	93
3.5.2	Comparison of sample extraction techniques	94
3.5.3	Analytical method validation	100
3.5.4	Determination of erectile dysfunction drugs in food samples	101
3.6	Conclusion	107
3.7	References	108
3.8	Supplementary data	115
CHAPTER 4	Determination of phosphodiesterase 5 (PDE5) inhibitors in instant coffee premixes using liquid chromatography-high-resolution mass spectrometry (LC-HRMS)	133
4.1	Foreword	133
4.2	Abstract	135
4.3	Introduction	137
4.4	Materials and methods	139
4.4.1	Chemicals and reagents	139
4.4.2	Standard solution preparation	139

4.4.3	Sample collection and storage	140
4.4.4	Sample preparation	140
4.4.5	LC-HRMS conditions	141
4.4.6	Method validation and data analysis	141
4.4.7	Workflow for determination of PDE5 inhibitors in instant coffee premixes	144
4.5	Results and discussion	149
4.5.1	Analytical method optimisation and validation	149
4.5.2	Analysis of PDE5 inhibitors in instant coffee premixes	151
4.6	Data on the optimisation and validation of a liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to establish the presence of phosphodiesterase 5 (PDE5) inhibitors in instant coffee premixes	158
4.6.1	Abstract	158
4.6.2	Experimental design, materials, and methods	161
4.6.3	Optimisation of chromatographic separation	163
4.6.4	Optimisation of MS conditions	166
4.6.5	Optimisation of sample preparation	167
4.6.6	Method validation	169
4.7	Conclusion	174

4.8	References	175
4.9	Supplementary data	180
CHAPTER 5	Isolation and identification of an isomeric sildenafil analogue as an adulterant in an instant coffee premix	182
5.1	Foreword	182
5.2	Abstract	184
5.3	Introduction	185
5.4	Materials and methods	187
5.4.1	Chemicals and reagents	187
5.4.2	Screening of food products	187
5.4.3	Standard solution preparation	189
5.4.4	Sample preparation	189
5.4.5	Isolation of compound X	189
5.4.6	LC-UV analysis	190
5.4.7	NMR Spectroscopy	190
5.4.8	Data analysis	191
5.5	Results and discussion	192
5.5.1	Screening of SPL005	192
5.5.2	LC-DAD and LC-UV of compound X	196
5.5.3	NMR spectroscopy of compound X	197
5.5.4	Confirmation of compound X	202
5.6	Conclusion	204
5.7	References	205
5.8	Supplementary data	209

CHAPTER 6	Suspected-target and non-targeted screenings of phosphodiesterase 5 inhibitors in herbal remedies by liquid chromatography-quadrupole time-of-flight mass spectrometry	210
6.1	Foreword	210
6.2	Abstract	212
6.3	Introduction	214
6.4	Materials and methods	217
6.4.1	Chemicals and reagents	217
6.4.2	Standard solution preparation	218
6.4.3	Sample collection and storage	218
6.4.4	Sample preparation	219
6.4.5	LC-QTOF-MS conditions and data analysis	220
6.4.6	Analytical method validation	221
6.4.7	Suspected-target and non-targeted screenings of herbal remedies	224
6.5	Results and discussion	226
6.5.1	Method optimisation	226
6.5.2	Analytical method validation	228
6.5.3	Screenings of herbal remedies for PDE5 inhibitors	229
6.6	Conclusion	243
6.7	References	244
6.8	Supplementary data	251

CHAPTER 7	Fluorescence polarisation for high-throughput screening of adulterated food products via phosphodiesterase 5 (PDE5) inhibition assay	266
7.1	Foreword	266
7.2	Abstract	268
7.3	Introduction	270
7.4	Materials and methods	273
7.4.1	Chemicals and reagents	273
7.4.2	Standard solution preparation	273
7.4.3	Sample collection and storage	274
7.4.4	Sample preparation	274
7.4.5	PDE5 inhibition assay protocol	275
7.4.6	LC-HRMS analysis	278
7.4.7	Data analysis	278
7.5	Results and discussion	280
7.5.1	PDE5 inhibition assay scheme	280
7.5.2	Optimisation of sample preparation	284
7.5.3	Assay validation	286
7.5.4	Analysis of PDE5 inhibitors in food products	288
7.6	Conclusion	296
7.7	References	297
CHAPTER 8	Conclusions and recommendations for future work	306

List of tables

		Page
Table 2.1	Tissue distribution of phosphodiesterase (PDE) enzymes found in human.	10
Table 2.4.2	Pharmacokinetic and pharmacodynamic properties of approved phosphodiesterase 5 (PDE5) inhibitors.	19
Table 2.4.5	Selectivity of approved phosphodiesterase 5 (PDE5) inhibitors (fold differences versus PDE5 enzyme) for clinically relevant phosphodiesterase (PDE) family.	24
Table 3.4.3	Contents of the blank food matrices based on the products' label.	85
Table 3.5.4	The identification of target analytes and the detection of suspected analytes in 25 food samples.	102
Table 3.8A	Matrix effect (ME) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors using dilute and shoot (D&S), liquid-liquid extraction (LLE), solid-phase extraction (SPE), and modified quick, easy, cheap, effective, rugged, and safe (QuEChERS) technique at 1:2 matrix dilution. (supplementary data)	115

Table 3.8B	Matrix effect (ME) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors using dilute and shoot (D&S), liquid-liquid extraction (LLE), solid-phase extraction (SPE), and modified quick, easy, cheap, effective, rugged, and safe (QuEChERS) technique at 1:10 matrix dilution. (supplementary data)	117
Table 3.8C	Matrix effect (ME) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors using dilute and shoot (D&S), liquid-liquid extraction (LLE), solid-phase extraction (SPE), and modified quick, easy, cheap, effective, rugged, and safe (QuEChERS) technique at 1:100 matrix dilution. (supplementary data)	119
Table 3.8D	Mean extraction recovery (RE) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors at low (0.1 µg/mL); medium (0.4 µg/mL); and high (1 µg/mL) quality control levels using liquid-liquid extraction (LLE) technique. (supplementary data)	121
Table 3.8E	Mean extraction recovery (RE) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors at low (0.1 µg/mL); medium (0.4 µg/mL); and high (1 µg/mL) quality control levels using solid-phase extraction (SPE) technique. (supplementary data)	123

Table 3.8F	Mean extraction recovery (RE) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors at low (0.1 µg/mL); medium (0.4 µg/mL); and high (1 µg/mL) quality control levels using modified quick, easy, cheap, effective, rugged, and safe (QuEChERS) technique. (supplementary data)	125
Table 3.8G	Retention time (RT), theoretical accurate mass of protonated molecule ([M+H] ⁺) precursor ion, product ions, coefficient of determination (r ²), and limit of detection (LOD) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors. (supplementary data)	127
Table 3.8H	Accuracy of 23 targeted phosphodiesterase 5 (PDE5) inhibitors at low (0.1 µg/mL); medium (0.4 µg/mL); and high (1 µg/mL) quality control levels. (supplementary data)	128
Table 3.8I	Repeatability of 23 targeted phosphodiesterase 5 (PDE5) inhibitors at low (L, 0.1 µg/mL); medium (M, 0.4 µg/mL); and high (H, 1 µg/mL) quality control levels. (supplementary data)	131
Table 3.8J	Intermediate precision of 23 targeted phosphodiesterase 5 (PDE5) inhibitors at low (L, 0.1 µg/mL); medium (M, 0.4 µg/mL); and high (H, 1 µg/mL) quality control levels. (supplementary data)	132

Table 4.5.2	The contents of phosphodiesterase 5 (PDE5) inhibitors in each sachet of instant coffee premix samples.	153
Table 4.6.5	Matrix effect (ME) for instant coffee premix using dilute and shoot (D&S) technique with methanol and modified quick, easy, cheap, effective, rugged, and safe (QuEChERS) procedure at three levels of dilution.	170
Table 4.6.6A	Retention time (RT), accurate mass of protonated molecule ($[M+H]^+$) precursor ion, mass error, and fragment ions of 23 targeted phosphodiesterase 5 (PDE5) inhibitors.	171
Table 4.6.6B	Coefficient of determination (r^2), accuracy, limit of detection (LOD), and limit of quantification (LOQ) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors.	172
Table 4.6.6C	Precisions, matrix effect (ME), and extraction recovery (RE) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors.	173
Table 5.5.1	Proposed common fragmentation patterns shared by dithiocarbodenafil group of analogues.	195
Table 5.5.3	^1H and ^{13}C nuclear magnetic resonance (NMR) data (δ in ppm, J in Hz) of compound X and structurally related phosphodiesterase 5 (PDE5) inhibitors.	198

Table 6.5.3A	Identification of target analytes and detection of suspected analytes in adulterated herbal remedy samples.	230
Table 6.5.3B	Suspected analytes detected from herbal remedy samples.	239
Table 6.8A	Sildenafil group of analogues. (supplementary data)	251
Table 6.8B	Acetildenafil group of analogues. (supplementary data)	253
Table 6.8C	Carbodenafil group of analogues. (supplementary data)	254
Table 6.8D	Vardenafil group of analogues. (supplementary data)	255
Table 6.8E	Tadalafil group of analogues. (supplementary data)	256
Table 6.8F	Miscellaneous phosphodiesterase 5 (PDE5) inhibitors. (supplementary data)	257
Table 6.8G	Phosphodiesterase 5 (PDE5) inhibitors and their analogues included in the personal compound database and library (PCDL). (supplementary data)	258
Table 6.8H	Matrix effect (ME) for capsule and tablet blank matrices using dilute and shoot (D) technique and modified quick, easy, cheap, effective, rugged, and safe (Q) extraction at three levels of matrix dilution. (supplementary data)	261

Table 6.8I	Retention time (RT), theoretical accurate mass of protonated molecule ($[M+H]^+$) precursor ion, mass error, product ions, coefficient of determination (r^2), and limit of detection (LOD) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors. (supplementary data)	262
Table 6.8J	Accuracy of 23 targeted phosphodiesterase 5 (PDE5) inhibitors. (supplementary data)	263
Table 6.8K	Precision of 23 targeted phosphodiesterase 5 (PDE5) inhibitors. (supplementary data)	264
Table 6.8L	Extraction recovery (RE) of 23 targeted phosphodiesterase 5 (PDE5) inhibitors. (supplementary data)	265
Table 7.4.5	Schematic three-step protocol of the phosphodiesterase 5 (PDE5) inhibition assay.	277
Table 7.5.4	Phosphodiesterase 5 (PDE5) inhibition assay results and confirmatory liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analysis of suspected adulterated food samples.	290

List of figures

		Page
Fig. 2.1	Structure of 3',5'-cyclic adenosine monophosphate (cAMP) and 3',5'-cyclic guanosine monophosphate (cGMP).	8
Fig. 2.2	Phosphodiesterase 5 (PDE5) enzyme molecular structure.	12
Fig. 2.4.3	Mechanism of action of phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction.	20
Fig. 2.4.4	Chemical structures of zaprinast and approved phosphodiesterase 5 (PDE5) inhibitors.	23
Fig. 2.5.3A	Chemical structures of sildenafil group of analogues with (a) sulphonamide-bonded analogues, (b) acetyl-bonded analogues, (c) carbonyl/thiocarbonyl-bonded analogues, and (d) other sildenafil-related analogues.	33
Fig. 2.5.3B	Chemical structures of vardenafil group of analogues with (a) vardenafil analogues and (b) thiovaridenafil analogues.	34
Fig. 2.5.3C	Chemical structures of tadalafil group of analogues with (a) cis-oriented with diketopiperazine ring analogues, (b) cis-oriented without diketopiperazine ring analogues, (c) trans-oriented with diketopiperazine ring analogues, and (d) trans-oriented without diketopiperazine ring analogues.	35

Fig. 3.5.2A	The matrix effect (ME) of dilute and shoot (D&S); liquid-liquid extraction (LLE); solid-phase extraction (SPE); and modified quick, easy, cheap, effective, rugged, and safe (QuEChERS) at 1:2, 1:10, and 1:100 matrix dilutions.	96
Fig. 3.5.2B	The extraction recovery (RE) of liquid-liquid extraction (LLE); solid-phase extraction (SPE); and modified quick, easy, cheap, effective, rugged, and safe (QuEChERS) at low (0.1 µg/mL); medium (0.4 µg/mL); and high (1 µg/mL) quality control levels.	99
Fig. 3.5.4	Results summary of erectile dysfunction drugs in adulterated food samples; with identification of target analytes and detection of suspected analytes.	105
Fig. 4.4.7	Liquid chromatography-high-resolution mass spectrometry (LC-HRMS) workflow for the determination of phosphodiesterase 5 (PDE5) inhibitors in instant coffee premixes.	145
Fig. 4.5.1	Representative extracted ion chromatogram (EIC) of the protonated molecule ($[M+H]^+$) precursor ion of 23 targeted phosphodiesterase 5 (PDE5) inhibitors mixture in neat solution at a concentration level of 1.2 µg/mL.	150

- Fig. 4.5.2 Comparison between dithiodesmethylcarbodenafil (20) from the personal compound database and library (PCDL) spectral library with the unknown compound X of sample SPL005 using the suspected-target screening approach with (a) overlaid extracted ion chromatogram (EIC) of the protonated molecule ($[M+H]^+$) precursor ion, (b) comparison of fragment ions based on common fragments at 20 eV collision energy, and (c) proposed common fragmentation pattern shared by dithiodesmethylcarbodenafil (20) and compound X (only showing two possible isomers, 3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil and dithiopropylcarbodenafil, among other isomeric variations). 157
- Fig. 4.6.3 Chromatographic separation of structural isomers with extracted ion chromatograms (EICs) of the protonated molecule ($[M+H]^+$) precursor ions of: Group A (m/z 439.2452): desmethylcarbodenafil (1) and N desethylacetildenafil (3); Group B (m/z 467.2765): acetildenafil (4) and dimethylacetildenafil (6); Group C (m/z 489.2279): vardenafil (7), homosildenafil (9), dimethylsildenafil (10), and propoxyphenyl-sildenafil (13); and Group D (m/z 505.2050): thiohomosildenafil (19) and thiodimethylsildenafil (21). 166

Fig. 4.9A	Chemical structures of 23 targeted phosphodiesterase 5 (PDE5) inhibitors. (supplementary data)	180
Fig. 4.9B	Results summary of phosphodiesterase 5 (PDE5) inhibitors in instant coffee premix samples. (supplementary data)	181
Fig. 5.5.1	(a) Base peak chromatogram (BPC) of SPL005 with one unidentified peak, initially assigned as compound X; (b) full-scan MS with a protonated molecule ($[M+H]^+$) precursor ion at m/z 499.2310 (also showing the matching scores of the observed mass, isotopic abundance distribution, and isotopic spacing of compound X with $C_{25}H_{34}N_6OS_2$); (c) product ion scan employing the non-targeted screening at m/z 343.0682 and m/z 371.0995; (d) common fragmentation patterns shared by compound X and dithiodesmethylcarbodenafil at averaged collision energies.	194
Fig. 5.5.2	Overlaid ultraviolet (UV) spectra of three structurally related phosphodiesterase 5 (PDE5) inhibitor standards at 1 μ g/mL and compound X isolated from SPL005.	196

Fig. 5.5.4	Overlaid base peak chromatograms (BPCs) of three structurally related phosphodiesterase 5 (PDE5) inhibitor standards at 1 µg/mL with (A) dithiodesmethylcarbodenafil, (B) 3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil, and (C) dithiopropylcarbodenafil; and (X) compound X isolated from SPL005.	203
Fig. 5.8	¹ H nuclear magnetic resonance (NMR) spectrum of the isolated compound X. (supplementary data)	209
Fig. 6.5.3A	Identification of target analytes and detection of suspected analytes in adulterated herbal remedy samples.	236
Fig. 6.5.3B	Quantification level of target analytes in adulterated herbal remedy samples.	238
Fig. 6.5.3C	Representative base peak chromatogram (BPC); overlaid extracted ion chromatograms (EICs) of aminotadalafil and tadalafil; and tandem MS spectra of sample SPT003 demonstrating the non-targeted screening based on top-down and bottom-up approaches.	240
Fig. 6.5.3D	The proposed common fragmentation pattern shared by the tadalafil group of analogues.	242

Fig. 7.5.1A	The structure of (a) sildenafil; (b) phosphodiesterase 5 (PDE5) enzyme; and (c) fluorescein-labelled cyclic-3',5'-guanosine monophosphate (FAM-cGMP) substrate.	281
Fig. 7.5.1B	Phosphodiesterase 5 (PDE5) inhibition assay scheme using fluorescence polarisation (FP) technique.	283
Fig. 7.5.2	Threshold values for each blank matrices of the food product.	285
Fig. 7.5.3	The concentration-response plot of sildenafil.	288

List of equations

		Page
Eq. 3.4.6A	$ME (\%) = \left[\frac{Slope_{post-extraction spiked matrix}}{Slope_{standards in neat solution}} - 1 \right] \times 100$	90
Eq. 3.4.6B	$RE (\%) = \frac{Peak\ area_{pre-extraction\ spiked\ matrix}}{Peak\ area_{post-extraction\ spiked\ matrix}} \times 100$	90
Eq. 4.4.6	$ME (\%) = \left[\frac{Slope_{matrix\ matched\ standards}}{Slope_{standards\ in\ neat\ solution}} - 1 \right] \times 100$	144
Eq. 4.4.7	$Final\ dose = \frac{Average\ conc.\ from\ reg.\ eq.}{(Analysis\ conc. \times Dilution\ level)} \times Wt.\ per\ sachet$	147
Eq. 7.4.7A	$FP (mP) = \frac{I_{ } - I_{\perp}}{I_{ } + I_{\perp}} \times 1000$	278

Eq. 7.4.7B % of PDE5 activity = $\frac{FP_{SPL} - FP_{SUB}}{FP_{POS} - FP_{SUB}} \times 100\%$ 279

Eq. 7.4.7C % of PDE5 inhibition = 100 - % of PDE5 activity 279

Eq. 7.4.7D $T_{inhibition} = \mu + 3\sigma$ 279

Eq. 7.4.7E $Y = Bottom + \frac{Top - Bottom}{1 + 10^{(Log IC_{50} - X) \times Hill Slope}}$ 279

List of abbreviations and symbols

%	percentage
%RSD	percentage of relative standard deviation
-	minus
+	plus
[M+H] ⁺	protonated molecule
<	less than
>	more than
±	plus, or minus
×	times
°C	degree Celsius
μ	average
μg	microgram
μL	microlitre
μm	micrometre
μM	micromolar
¹³ C	carbon-13
¹ H	hydrogen-1 or proton
AMP	5'-adenosine monophosphate
AOAC	The Association of Official Agricultural Chemists
BPC	base peak chromatogram
brs	broad singlet
Ca ²⁺	calcium
cAMP	3',5'-cyclic adenosine monophosphate

Cap	capsule
CDCl ₃	deuterated chloroform
CE	collision energy
cGMP	3',5'-cyclic guanosine monophosphate
CI	chemical ionisation
CID	collision-induced dissociation
COOH	carboxyl
CRM	certified reference material
CWG	chewing gum
CYP3A4	cytochrome P3A4
d	doublet
D&S	dilute and shoot
Da	Dalton
DAD	diode array detector
dd	doublet of doublet
DDA	data-dependent acquisition
DMSO	dimethyl sulfoxide
ED	erectile dysfunction
EFS	electrical field stimulation
EIC	extracted ion chromatogram
Eq.	Equation
ESI	electrospray ionisation
eV	electronvolt
FAM-cGMP	fluorescein-labelled cyclic-3',5'-guanosine monophosphate
FAM-GMP	fluorescein-labelled 5'-guanosine monophosphate

Fig.	Figure
FP	fluorescence polarisation
FP _{POS}	fluorescence polarisation (positive control)
FP _{SPL}	fluorescence polarisation (sample)
FP _{SUB}	fluorescence polarisation (substrate control)
FT-ICR	Fourier transform-ion cyclotron resonance
FTIR	Fourier transform infrared
<i>g</i>	gravity
g	gram
GC	guanylyl cyclase
GC-MS	gas chromatography-mass spectrometry
GC-QQQ-MS	gas chromatography-triple quadrupole mass spectrometry
GMP	5'-guanosine monophosphate
GTP	guanosine triphosphate
HCD	hard candy
HNY	honey
HPLC	high-performance liquid chromatography
HPTLC	high-performance thin-layer chromatography
HRMS	high-resolution mass spectrometry
Hz	hertz
I	parallel emission light intensities
I _⊥	perpendicular emission light intensities
IC ₅₀	half-maximal inhibitory concentration
ICH	The International Conference on Harmonisation
ICP	instant coffee premix

IR	infrared
IS	internal standard
IT	ion trap
IUPAC	The International Union of Pure and Applied Chemistry
<i>J</i>	coupling constants
JLY	jelly
L	litre
LC	liquid chromatography
LC-DAD	liquid chromatography-diode array detection
LC-HRMS	liquid chromatography-high-resolution mass spectrometry
LC-MS	liquid chromatography-mass spectrometry
LC-MS/MS	liquid chromatography-tandem mass spectrometry
LC-QTOF-MS	liquid chromatography-quadrupole time-of-flight mass spectrometry
LC-UV	liquid chromatography-ultraviolet
LLE	liquid-liquid extraction
LOD	limit of detection
Log P	logarithm of the partition coefficient
Log ₁₀	logarithm with base 10
LOQ	limit of quantification
m	multiplet
M	molar mass
<i>m/z</i>	mass-to-charge ratio
MDMA	3,4-methylenedioxymethamphetamine
ME	matrix effect

mg	milligram
MHz	megahertz
min	minute
mL	millilitre
mm	millimetre
mM	millimolar
mP	millipolarisation
MRM	multiple reaction monitoring
MS	mass spectrometry
ms	millisecond
MS/MS	tandem mass spectrometry
MΩ-cm	megaohm-centimetre
NA	not applicable
ND	not detected
ng	nanogram
NH ₂	amino
NIR	near-infrared
nM	nanomolar
nm	nanometre
NMR	nuclear magnetic resonance
NO	nitric oxide
P	phosphorylation
PCDL	personal compound database and library
PDA	photodiode array
PDE	phosphodiesterase

PDE5	phosphodiesterase 5
PDM	powdered drink mix
pg	picogram
pH	power of hydrogen
pK _a	negative log of acid dissociation constant
PKG	3',5'-cyclic guanosine monophosphate-dependent protein kinase
ppm	parts per million
psi	pounds per square inch
psig	pounds per square inch gauge
PTFE	polytetrafluoroethylene
Pty Ltd.	Proprietary Limited
Q	single quadrupole
q	quartet
QC	quality control
QQQ	triple quadrupole
QTOF	quadrupole time-of-flight
QTOF-MS	quadrupole time-of-flight mass spectrometry
QuEChERS	quick, easy, cheap, effective, rugged, and safe
R ²	coefficient of determination (curve)
r ²	coefficient of determination (linear)
RE	extraction recovery
RT	retention time
s	singlet
SD	standard deviation

sec	second
SERS	surface-enhanced Raman spectroscopy
SPE	solid-phase extraction
SPR	supratherapeutic
SUB	subtherapeutic
t	triplet
Tab	tablet
THE	therapeutic
T _{inhibition}	threshold value of phosphodiesterase 5 inhibition
TLC	thin-layer chromatography
T _{max}	the amount of time that a drug is present at the maximum concentration in serum
TOF	time-of-flight
TRC	trace
U	unit
USFDA	The United States Food and Drug Administration
UV	ultraviolet
UV-Vis	ultraviolet-visible
V	volt
v/v	volume/volume
WHO	The World Health Organization
Zn ²⁺	zinc
α	alpha
δ	chemical shifts
σ	standard deviation

List of peer-reviewed journal publications

1. Mohd Yusop AY, Xiao L, Fu S. Determination of Chapter 4
phosphodiesterase 5 (PDE5) inhibitors in instant coffee
premixes using liquid chromatography-high-resolution mass
spectrometry (LC-HRMS). *Talanta* 2019;204:36-43.
doi:<https://doi.org/10.1016/j.talanta.2019.05.078>
2. Mohd Yusop AY, Xiao L, Fu S. Data on the optimisation and Chapter 4
validation of a liquid chromatography-high-resolution mass
spectrometry (LC-HRMS) to establish the presence of
phosphodiesterase 5 (PDE5) inhibitors in instant coffee
premixes. *Data Brief* 2019;25:104234.
doi:<https://doi.org/10.1016/j.dib.2019.104234>
3. Mohd Yusop AY, Xiao L, Fu S. Suspected-target and non- Chapter 6
targeted screenings of phosphodiesterase 5 inhibitors in
herbal remedies by liquid chromatography-quadrupole time-
of-flight mass spectrometry. *Drug Test Anal* 2020.
doi:<https://doi.org/10.1002/dta.2861>
4. Mohd Yusop AY, Xiao L, Fu S. Fluorescence polarisation for Chapter 7
high-throughput screening of adulterated food products via
phosphodiesterase 5 (PDE5) inhibition assay. *Drug Test Anal*
2020. doi: <https://doi.org/10.1002/dta.2926>

List of manuscripts submitted to peer-reviewed journal publications

1. Mohd Yusop AY, Xiao L, Fu S. Comparison of sample extraction techniques for the determination of erectile dysfunction drugs as adulterants in selected food products. Chapter 3
Manuscript submitted for publication 2020.
2. Mohd Yusop AY, Xiao L, Fu S. Isolation and identification of an isomeric sildenafil analogue as an adulterant in an instant coffee premix. Chapter 5
Manuscript submitted for publication 2020.

List of peer-reviewed conference proceedings
(presenting author underlined)

1. Mohd Yusop AY, Xiao L, Fu S. Mitigating matrix effects: an evaluation of sample extraction techniques for forensic investigations of synthetic aphrodisiacs illegally added into consumable products. *The 56th Annual Meeting of The International Association of Forensic Toxicologists*. Ghent, Belgium. 26–30 August 2018.
2. Mohd Yusop AY, Xiao L, Fu S. Strategies to overcome matrix effect for reliable determination of sexual enhancing drugs found as adulterants in premixed coffee. *The Australian and New Zealand Forensic Science Society 24th International Symposium*. Perth, Australia. 9–13 September 2018.
3. Mohd Yusop AY, Xiao L, Fu S. Adulterant detection in herbal dietary supplements marketed to enhance male sexual performance. *The Forensic and Clinical Toxicology Association Inc. 10th Conference*. Adelaide, Australia. 16–19 June 2019.
4. Mohd Yusop AY, Xiao L, Fu S. Application of liquid chromatography-high resolution mass spectrometry (LC-HRMS) to determine male sexual stimulant in selected food matrices. *The 57th Annual Meeting of The International Association of Forensic Toxicologists*. Birmingham, United Kingdom. 2–6 September 2019.

5. Mohd Yusop AY, Xiao L, Fu S. Safeguarding food safety: rapid screening of phosphodiesterase 5 (PDE5) inhibitors as adulterants in selected food matrices using enzyme assay. *The 55th Congress of the European Societies of Toxicology (EUROTOX 2019)*. Helsinki, Finland. 8–11 September 2019.